Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

A3087794-0009-4fac-a2e0-773dd69fc822 - samples

ABSTRACT: Data from NABUCCO cohort 1 (NCT03387761). This dataset includes Whole exome DNA sequencing on bladder tumor samples (n=24) matched with blood samples (n=24). The data is pre-treatment.

PROVIDER: EGAD00001006850 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

5c8d51a7-6ae9-4ebd-aa2e-826d72764981 - samples

Project description:Data from NABUCCO cohort 2 (NCT03387761). This dataset includes Whole exome DNA sequencing on bladder tumor samples matched with blood samples for patients from NABUCCO Cohort 2 (Cohort 2A and Cohort 2B). The data is pre-treatment

| EGAD00001009864 | EGA

986e3270-53f6-45e1-8d37-74dd7fca6cd7 - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes High coverage Whole exome DNA sequencing on pre-treatment bladder tumor samples (n=3) matched with post-treatment metastasised adjacent lymph nodes isolated with laser microdissection (n=3) for 3 unique patients

| EGAD00001006852 | EGA

b936ede5-2834-4507-aff2-da873230567d - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes Tumor mutational burden (TMB) calculated on bladder tumor pre-treatment DNA sequencing data (n=24). Details about the Tumor Mutational Burden calculation can be found on the Methods section from the Nature Medicine paper (https://doi.org/10.1038/s41591-020-1085-z)

| EGAD00001006851 | EGA

8ab494b0-a700-4578-9ecc-943c4df785e7 - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the pre-treatment PD-L1 staining on tumor samples (n=24). Details about the PD-L1 staining can be found on the paper (https://doi.org/10.1038/s41591-020-1085-z)

| EGAD00001006856 | EGA

1c7fd278-9637-4dbc-9473-4adb93cddc92 - samples

Project description:NABUCCO cohort 1 sequencing data. The dataset includes RNA sequencing pre-treatment on tumor samples (n=18) and RNA sequencing post-treatment on bladder tumor samples (n=18).

| EGAD00001006855 | EGA

46986158-75a7-4bd5-9c84-274e0ec775c0 - samples

Project description:NABUCCO cohort 1 sequencing data. The dataset includes: * Whole exome DNAseq pre-treatment on tumor samples (n=24) matched with blood samples (n=24) * RNAseq pre-treatment on tumor samples (n=18) * RNAseq post-treatment on tumor samples (n=18). Not all pre-treatment samples are linked with pre-treatment samples * High coverage Whole exome DNAseq on pre-treatment tumor samples (n=3) matched with post-treatment metastasized lymph nodes isolated with laser microdissection (n=3) * All samples are labelled with the response phenotype (Complete Responder or Non-Complete Responder)

| EGAD00001006250 | EGA

14b69200-68f9-43e1-b8fc-19b810ecdbbe - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the Transcript read counts derived from the RNA sequencing data. The samples are pre-treatment (n=18) and post-treatment (n=18), and not all samples are paired. The data processing pipeline can be found on the Methods section from the Nature Medicine paper (https://doi.org/10.1038/s41591-020-1085-z)

| EGAD00001006854 | EGA

In-depth plasma proteomics in patients with metastatic cutaneous melanoma treated with immune checkpoint inhibitors or MAPK-inhibitors

Project description:Recent development of new therapies with immune checkpoint inhibitors (ICIs) and MAPK-inhibitors (MAPKis) have significantly improved the outcome in metastatic cutaneous melanoma (CM). However, therapy response is limited to subgroups of patients and clinically useful predictive biomarkers for treatment outcome are lacking. To discover treatment-related systemic changes in plasma and potential biomarkers associated with treatment outcomes, we analysed 45 plasma samples from 24 patients with metastatic (stage IV) CM, using HiRIEF LC-MS/MS, collected before (pre-trm) and during treatment (trm). Of these, 27 samples were taken from 15 metastatic CM patients treated with ICIs (13 pre-trm and 14 trm samples; 12 matched) and 9 patients treated with MAPKis (9 matched). Matched samples were trm and pre-trm samples taken from the same individual before treatment and after the first cycle of treatment (before the second cycle). We have analysed the change in the plasma protein levels during treatment by comparing the plasma levels in the trm samples to the pre-trm samples, to detect treatment-induced alterations in the plasma proteome. We have analysed the patients treated with ICIs separately from the patients treated with MAPKis, to detect treatment-specific changes for both.

2020-07-13 | PXD017201 | Pride

294264a0-6fff-481a-873e-31e55f1c19ea - samples

Project description:Data from NABUCCO cohort 1 (NCT03387761). This dataset includes the Response labels used for the analysis of the data. Details about the clinical definitions of Response can be found on the paper (https://doi.org/10.1038/s41591-020-1085-z)

| EGAD00001006853 | EGA

Evolution of core archetypal phenotypes in high-grade serous ovarian cancer (HGSOC)

Project description:24 malignant fluid samples were collected from 9 high-grade ovarian cancer patients at various time points over the course of chemotherapy. Additionally, an independent cohort of 8 malignant fluid samples were collected from pre-treatment patients and 7 samples from post-treatment patients. Single-cell RNA sequencing (scRNA-seq) was performed using 10X or iCell8 technologies.

2021-02-09 | GSE158722 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data